Table 1.
PGS in combination with | Solvents | Mechanical properties | Other specifics | Cells/animal model | Cellular response | Proposed application | Refs. |
---|---|---|---|---|---|---|---|
PCL | CF/EtOH |
YM: 6.3 MPa (random) ‐ 9.6 MPa (aligned) UTS: ‐ Strain: ‐ |
Aligned fibers | HUVECs | Enhanced cellular proliferation and organization by alignment; formation of highly organized endothelial constructs | Vascular TE | [ 105 ] |
PCL, VEGF | DCM/MeOH |
YM: 8 ± 2 MPa UTS: 3 ± 0.5 MPa Strain: 142 ± 29% |
VEGF functionalization; potential for the formation of vascular tree in fiber mat | C2C12 myoblasts, rat cardiac progenitor cells, rat aortic endothelial cells | Attachment and growth of myogenic and vasculogenic cell lines | CTE | [ 106 ] |
Sacrificial PVA, PCL | HFIP (PGS/PVA), TFE/H2O (PCL) | YM: 0.67– 0.871 MPa | Removal of PVA leaving neat PGS fibers behind | In vivo mice model | No thrombosis or stenosis; organization of contractile SMCs and neotissue in the inner part of the graft, macrophage driven‐inflammatory response to remaining polymer up to 12 months postimplantation | Vascular TE | [ 107 ] |
PCL | DCM/MeOH | – | Patterned topography | C2C12 myoblasts, neonatal rat cardiomyocytes | Alignment of both cell types due to the surface topography | CTE | [ 110 ] |
PCL | CF/EtOH |
YM: 4.25– 7.61 MPa UTS: 1.78– 3.14 MPa Strain: 218 – 453% |
Good anticoagulation property with low hemolysis percentage | Human vascular endothelial cell line EAhy926 | Good biocompatibility | Vascular TE | [ 111 ] |
PCL, silver | CF/EtOH |
YM: 3.3 MPa (uncoated) –≈8 (with Ag) MPa UTS: ≈1.5 (uncoated) ‐ ≈2.6 (with Ag) MPa Strain: ≈200 (uncoated) ‐ ≈175 (with Ag) % |
Silver coating with antibacterial properties | – | – | Diverse | [ 45 ] |
PCL | CF/EtOH | – | Aligned fibers | Human corneal epithelial cells, human corneal keratocytes | Good biocompatibility, formation of a confluent cell layer | Corneal TE | [ 38 ] |
PCL | CF/EtOH |
Surface moduli of 0.26 GPa, 0.29 GPa, 0.12 GPa, and 0.16 GPa for PGS/PCL 4:1, 3:1, 2:1 1:1 |
Aligned fibers | Human corneal endothelial cells, human conjunctival epithelial cells, and PBMCs | Best cell organization, cyto‐ and immunocompatibility in a higher content of PGS in PGS–PCL blend | Corneal TE | [ 16 ] |
PCL, silver | CF/EtOH | – | Silver coating with pattern | NIH 3T3 fibroblasts | Good biocompatibility | Diverse | [ 97 ] |
PCL, PEGylated‐CH nanoparticles | CF/EtOH | – | Additional patterning of a bioresorbable metallic heater for thermal stimulation of on‐demand antibiotic release; antibacterial properties | Keratinocytes | Good biocompatibility | Wound healing, drug delivery | [ 19 ] |
PCL, gelatin, dexamethasone | CF/MeOH (PGS‐PCL‐dex), AcOH/H2O (gelatin) |
YM: 6.3 (wet) ‐7.8 (dry) MPa UTS: 0.74 (dry) ‐1.64 (wet) MPa Strain: 36.8 (dry) ‐ 102 (wet) % |
Sustained drug release for 30 d | Gingival fibroblast cells | No evidence of cytotoxicity; cell proliferation not adversely affected by Dex release | Soft TE | [ 98 ] |
PCL, heparin | TFE |
YM: ≈3 –≈15.5 MPa UTS: ≈2–≈4 MPa Strain: ≈250 –≈900% |
Heparin functionalization | HUVECs | Improved cell attachment and proliferation after grafting of heparin | Diverse | [ 99 ] |
PCL, CH, β‐TCP | CF (PGS‐PCL‐β‐TCP), TFA (PGS‐PCL‐CH) |
YM: ‐ UTS: ≈1.1 –≈1.4 MPa Strain: ≈0.8 –≈2.4 |
Bilayered | Human fetal osteoblasts | Optimum cell behavior in blend composition with 10% β‐TCP | BTE | [ 51 ] |
PCL, hydroxyapatite nanoparticles | d.n.a. | d.n.a. | d.n.a. | Bone marrow‐derived MSCs | Excellent biocompatibility and osteoblast adhesion | Bone and cartilage TE | [ 100 ] |
PCL | CF/acetone (PGS‐PCL), AcOH/FA (PCL) |
YM: 2.6– 3.1 MPa UTS: 0.8– 1.5 MPa Strain: ≈58 –≈65% |
Nonhemolytic behavior | MSCs | Supported attachment, growth, and infiltration of cells by blend fiber mat | Vascular TE | [ 101 ] |
PCL | AcOH |
YM: 7– 11 MPa UTS: 4.4– 5 MPa Strain: 304–333% |
Use of mildly cross‐linked PGS for electrospinning | Bone marrow‐derived stroma cell line ST2 | Better cytocompatibility and cell adhesion after sterilization by 70% ethanol compared to UV sterilization | CTE | [ 33 ] |
PCL | CF/EtOH/DMF |
YM: 8.32 (dry) – 8.62 (wet) MPa UTS: ‐ Strain: 783 (dry)–1133 (wet) % |
Bilayered construct with PU membrane layer | Mouse lung fibroblast cells (L929), HUVECs | No toxic effect of leachable components on fibroblasts; endothelial cell adhesion and proliferation on PGS/PCL fiber mat | Hernia treatment | [ 104 ] |
PCL, KGN | TFE |
YM: 5.06 (nonaligned)– 11.78 (aligned) MPa UTS: ≈2.3 (non‐aligned) –≈3 (aligned) MPa |
Aligned core–shell fibers | Human bone marrow MSC (hBMSC) | Significant proliferation and chondrogenic differentiation on KGN‐loaded aligned nanofibrous scaffold | Cartilage TE | [ 103 ] |
Sacrificial PVA | H2O (PVA), THF (PGS) |
YM: ≈3 MPa (wet) –≈33 MPa (dry) UTS: ≈ 1.5 MPa (wet) –≈7 MPa (dry) Strain: 95 % (wet)– ≈130% (dry) |
PGS only fibers | SNL mouse fibroblasts | Good biocompatibility | Soft TE | [ 133 ] |
Sacrificial PVA | HFIP |
YM: 0.1– 0.8 MPa UTS: ≈1 MPa Strain: 200 –800% |
PGS only fibers | 3T3 fibroblasts, Human cord blood endothelial cells (hcbEC), in vivo mice model |
Round to elongated adhered cell morphology; higher cytocompatibility of highly cross‐linked materials; In vivo: surrounded by collagen‐rich matrix and multinucleated giant cells and fibroblast‐like cells in implant bulk |
Diverse | [ 96 ] |
PVA | DMF/H2O |
YM: 0.04 (wet)– 7.08 (dry) MPa UTS: 2 (dry)–70 (dry) MPa Strain: 34.5 (dry)–287 (wet) % |
Modified PGS synthesis (1:0.8 molar mixture of glycerol and sebacic acid; 170 °C; 3, 5, and 7 h); Aligned fibers |
Rat pheochromocytoma cells (PC12) | Good biocompatibility | Nerve TE | [ 114 ] |
PVA, lignin | H2O, DMF |
YM: 0.1– 0.4 MPa UTS: 20.24–72.8 MPa Strain: 51– 179.5% |
– | Rat pheochromocytoma cells PC12 | Cell proliferation and neural cell differentiation in the presence of lignin | Nerve TE | [ 113 ] |
PLLA | CF/DMF (PLLA), THF (PGS) |
YM: 6.5– 15.8 MPa UTS: 2.2– 4.5 MPa Strain: 25.1–43.4% |
Aligned core–shell fibers | – | – | Diverse | [ 118 ] |
PLLA | DMF/DMC |
YM: 7.2– 336.2 MPa UTS: 1.1– 6.8 MPa Strain:13– 66% |
During cross‐linking creation of core (PLLA)–shell (PGS) fibers | Hypothalamus A59 nerve cells | Enhanced cell adhesion and proliferation for core–shell samples | Nerve TE | [ 119 ] |
PLGA | HFIP (PGS), NaCl, SRB dye, HFIP (PLGA) | – | – | – | – | Diverse | [ 121 ] |
PLGA | HFIP |
YM: 1.3 ± 0.66 MPa UTS: ‐ Strain: – |
– | SIMS salivary ductal epithelial cell, NIH3T3 mesenchymal cells | Cell penetration in the structure and apical localization of tight junction proteins; coculture facilitated epithelial tissue reorganization and significantly increased apical localization of tight junction protein | Soft TE | [ 122 ] |
PLA | HFIP | – | Different esterification levels of PGS | – | – | Diverse | [ 117 ] |
Sacrificial PEO/PLA | THF (PGS), THF/DMF (PEO/PLA) |
YM: ≈1– 140 MPa UTS: ≈0.5–6 MPa Strain: ≈1.05–2.5% |
PGS only fibers | HUASMCs | Good biocompatibility | Soft TE | [ 120 ] |
Sacrificial PEO/PLA | THF (PGS), DCM/DMF (PEO‐PLA) |
YM: ≈0.5 (perpendicular) – ≈ 1 (in alignment) MPa UTS: ≈0.36 (perpendicular) –≈0.72 (in alignment) MPa Strain: ≈160 (perpendicular) – ≈ 170 (in alignment) % |
Aligned core–shell fibers | HUASMCs | Cell adhesion on random and aligned fibers, and cell alignment on aligned fibers | Diverse | [ 134 ] |
Collagen type I, silk fibroin | HFIP |
YM: 2.3– 5.0 MPa UTS: 0.8– 1.5 MPa Strain: 30–70% |
Low thrombogenic potential | Endothelial cells | Cells adhered, proliferated, and formed cell–cell junctions | Vascular TE | [ 127 ] |
Fibrinogen, VEGF | HFIP | – | VEGF functionalization | In vivo porcine model | Improvement in ejection fraction (EF) and prevention of LV enlargement; expression of cardiac marker proteins | CTE | [ 129 ] |
PBS‐DLA | DCM/MeOH |
YM: 1.2– 7.5 MPa UTS: 1.58–2.7 MPa Strain: 85.5–147.6% |
– | C2C12 myoblasts, postnatal rat cardiomyocytes | Cytocompatibility with C2C12 myoblasts, the higher the PBS–DLA content in the fiber mats, the better the cell attachment and proliferation; postnatal rat cardiomyocytes better attachment on higher PGS content fibers with well‐aligned sarcomeres and high amounts of connexin43 | CTE | [ 115 ] |
PBS‐DLS | DCM/MeOh |
YM: 3.5 (37 °C)–4.7 (RT) MPa UTS: 1.23 (37 °C)– 1.8 (RT) MPa Strain: ≈132% |
Surface modification by exposing carboxylic groups | – | – | Soft TE | [ 116 ] |
Zein | AcOH |
YM: 6.5– 14 MPa UTS: 0.32–13 MPa Strain: 5–7% |
– | – | – | CTE | [ 130 ] |
Zein | AcOH |
YM: 7– 32 MPa UTS: 1–‐ 2 MPa Strain: 5– 11 MPa |
Use of mildly cross‐linked PGS for electrospinning | – | – | Soft TE | [ 131 ] |
PGS–PMMA, gelatin | HFIP | – | Methyl mAcr–PGS | Rat PC12 cells | Fiber mats promoted cell proliferation, elongated cell morphology, potential for neurite outgrowth | Nerve TE | [ 20 ] |
PSF | THF/DMF | – | Compressible, moldable, 3D, drug delivery | In vivo mice model | – | Diverse | [ 123 ] |
Chitin, Lignin, PEO | EtOH, NaOH, H2O |
YM: ≈7–≈12 MPa UTS: ≈0.75 –≈3 MPa Strain: ≈20 –≈140% |
Antibacterial and antifungal activity | – | – | Wound healing | [ 132 ] |
SIM, PHB, CIP | CF/DMF(PGS‐Sim), TFA (PHB‐CIP) | – | Dual drug incorporation in core–shell fibers; burst release of CIP, slower release SIM; antibacterial activity | – | – | Wound healing | [ 124 ] |
Gelatin, CIP | Aqueous AcOH | – | Antibacterial activity | Fibroblast cell line (L929) | Promoted cell attachment, growth, proliferation, and immigration from the surface into interconnected pores | Wound healing | [ 128 ] |
TPU |
CF/DMF or HFIP or TFE/AcOH |
YM: 0.83– 1.14 MPa UTS:8.76–9.67 MPa Strain: 339–375% |
Leaf‐like structure observed for HFIP | Swiss mouse NIH 3T3 fibroblasts | Improved biocompatibility compared to TPU only scaffolds | Vocal fold TE | [ 35 ] |
PVP | HFIP (PGS), DMF/EtOH/H2O (PVP) |
YM: 1.3– 170 MPa UTS: 1.1– 3.5 MPa Strain: 3.1–328% |
Nozzle free electrospinning | Human skin fibroblast cells (HDF‐hTERT) | Good cell viability and proliferation | Skin TE | [ 232 ] |
Poly(glycerol‐1,8‐octanediol‐sebacate) | CF/EtOH |
YM: 3.61 MPa uncross‐linked, 106.1 MPa cross‐linked UTS: 0.13 MPa uncross‐linked, 4.94 MPa cross‐linked Strain: 8% uncross‐linked, 23% cross‐linked |
PGS synthesized by Candida antartica lipase B catalysis; different fractions of glycerol units replaced by 1,8‐octanediol units | – | – | Diverse | [ 135 ] |